Age dependence of modern clinical risk groups for localized prostate cancer-A population-based study.

Abstract

Optimal prostate cancer (PCa) screening strategies will focus on men likely to have potentially lethal disease. Age-specific incidence rates (ASIRs) by modern clinical risk groups could inform risk stratification efforts for screening. This cross-sectional population study identified all men diagnosed with PCa in Norway from 2014 to 2017 (n=20,356). Age, Gleason score (primary plus secondary), and clinical stage were extracted. Patients were assigned to clinical risk groups: low, favorable intermediate, unfavorable intermediate, high, regional, and metastatic. Chi-square tests analyzed the independence of Gleason scores and modern PCa risk groups with age. ASIRs for each risk group were calculated as the product of Norwegian ASIRs for all PCa and the proportions observed for each risk category. Older age was significantly associated with a higher Gleason score and more advanced disease. The percentages of men with Gleason 8 to 10 disease among men aged 55 to 59, 65 to 69, 75 to 79, and 85 to 89years were 16.5%, 23.4%, 37.2%, and 59.9%, respectively (P<.001); the percentages of men in the same age groups with at least high-risk disease were 29.3%, 39.1%, 60.4%, and 90.6%, respectively (P<.001). The maximum ASIRs (per 100,000 men) for low-risk, favorable intermediate-risk, unfavorable intermediate-risk, high-risk, regional, and metastatic disease were 157.1 for those aged 65 to 69years, 183.8 for those aged 65 to 69years, 194.8 for those aged 70 to 74years, 408.3 for those aged 75 to 79years, 159.7 for those aged ≥85years, and 314.0 for those aged ≥85years, respectively. At the ages of 75 to 79years, the ASIR of high-risk disease was approximately 6 times greater than the ASIR at 55 to 59years. The risk of clinically significant localized PCa increases with age. Healthy older men may benefit from screening.